Daptomycin vs Vancomycin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Daptomycin or Vancomycin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Daptomycin and Vancomycin?
Vancomycin requires therapeutic drug monitoring due to nephrotoxicity; daptomycin avoids renal toxicity but is inactivated by pulmonary surfactant and cannot treat pneumonia - each has a critical clinical limitation the other does not.
Evidence Comparison
Both have extensive Phase 3 data and decades of clinical use. Vancomycin: gold-standard glycopeptide with 60+ years of use, nephrotoxicity and ototoxicity are well-characterized risks. Daptomycin: FDA approved 2003, non-inferior to vancomycin for S. aureus bacteremia (Fowler 2006, NEJM). Evidence is comparably robust.
Evidence Context Favoring Daptomycin
MRSA bacteremia or complicated skin infections, especially in patients with renal impairment where vancomycin nephrotoxicity is a concern.
Evidence Context Favoring Vancomycin
Empiric Gram-positive coverage, pneumonia, or settings where therapeutic drug monitoring infrastructure exists and vancomycin's longer track record matters.
Side-by-Side Snapshot
| Evidence grade | Daptomycin: Level A Vancomycin: Level A |
|---|---|
| Research status | Daptomycin: FDA Approved Vancomycin: FDA Approved |
| Primary category | Daptomycin: Immune Support Vancomycin: Immune Support |
| Cited studies | Daptomycin: 3 Vancomycin: 3 |